Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Healthcare company Integrated Diagnostics reported a rise in first-quarter profit amid strong demand for its Covid-19 test offering.
For the first three months of 2021, net profit was EGP 339 million, up 230% year-on-year in 1Q 2021, and revenue rose 126% to EGP 1,130 million.
'The record-breaking performance in the first quarter of 2021 was primarily supported by IDH's Covid-19-related test offering and was both volume- and price-driven, as total tests performed expanded 32% year-on-year and average revenue per test increased 71% versus 1Q 2020,' the company said.
Net profit margin stood at 30% for the quarter versus 21% in 1Q 2020.
'Looking ahead, while the company's immediate focus remains on continuing to play a frontline role in helping governments across our footprint combat the ongoing Covid-19 pandemic, IDH's longer-term outlook remains strong as evidenced by the recovery of our conventional business witnessed in the first quarter of 2021,' the company said.
At 9:35am: (LON:IDHC) Integrated Diagnostics Holdings Plc share price was 0p at 3.93p